Sector News

Bayer to acquire gene therapy specialist AskBio for $4bn

November 1, 2020
Life sciences

Bayer has announced the acquisition of US-headquartered cell and gene therapy specialist Asklepios BioPharmaceutical (AskBio) in a deal worth $4bn.

Under the deal, AskBio will get an upfront payment of $2bn from Bayer and is eligible for success-based milestone payments of up to $2bn.

Approximately 75% of the milestone payments will be paid in a course of five years and the remaining amount subsequently.

Even after the acquisition, AskBio will operate as an independent company.

AskBio’s development portfolio comprises investigational pre-clinical and clinical-stage candidates for treating neuromuscular, central nervous system, cardiovascular and metabolic diseases.

The deal will strengthen Bayer’s emerging cell and gene therapy (CGT) platform with the potential to bring treatments to diseases with high unmet need.

Bayer Board of Management (CEO) chairman Werner Baumann said: “With this acquisition, Bayer significantly advances the establishment of a cell and gene therapy platform that can be at the forefront of breakthrough science, contributing to preventing or even curing diseases caused by gene defects and further driving company growth in the future.”

On acquisition completion, Bayer will have full rights to AskBio’s gene therapy platform which consists of a broad intellectual property portfolio and an established contract development and manufacturing organisation (CDMO).

Bayer will add an adeno-associated virus (AAV)-based gene therapy platform to its portfolio, which already showed applicability in various treatment areas.

AskBio’s gene therapy platform includes a cell line manufacturing process and an extensive AAV capsid and promoter library.

Asklepios BioPharmaceutical chief scientific officer and co-founder Dr Richard Samulski said: “Our innovation in capsid re-engineering and promoter design, coupled with our scaled manufacturing processes, gives us the tools to provide gene therapy solutions to more people suffering from a wider spectrum of disease that is not being adequately treated today.”

On meeting customary closing conditions including obtaining required regulatory approvals, the closing of the transaction is expected by the fourth quarter of this year.

By Pharmaceutical-technology.com

Source: pharmaceutical-technology.com

Related News

June 19, 2021

P&G-backed Kindra to tap into overlooked menopause sector after landing US$4.5M

Life sciences

Kindra has closed a US$4.5 million seed funding round to expand and grow its menopause offerings. The US-based brand, which is backed by P&G Ventures, aims to drive a cultural shift around menopause, which has been “long overlooked.”

June 19, 2021

Johnson & Johnson among companies excluding Colorado residents from remote job openings after new state law

Life sciences

Colorado established a new law this year requiring companies to divulge a salary range on job postings. But some large companies, like Johnson & Johnson, McKesson and Cardinal Health, have responded by barring candidates from the state.

June 19, 2021

Former Emisphere investors sue over ‘ill-timed’ $1.8B sale to Novo Nordisk

Life sciences

Former Emisphere stockholder IsZo Capital is one of several parties seeking damages against controlling stockholder MHR Fund Management for allegedly “co-opting” the drug delivery specialist’s board and forcing an “ill-timed” sale to Novo Nordisk at an “artificially low price,” a new lawsuit says.

Send this to a friend